(Press-News.org) New Haven, Conn. — A multi-center phase I study using an investigational drug for advanced bladder cancer patients who did not respond to other treatments has shown promising results in patients with certain tumor types, researchers report. Yale Cancer Center played a key role in the study, the results of which will be presented Saturday, May 31 at the 2014 annual conference of the American Society of Clinical Oncology (ASCO) in Chicago.
The trial included 68 people with previously treated advanced bladder cancer, including 30 patients identified as PD-L1 positive. PD-L1 is a protein expressed by many tumor types that can render the cancer invulnerable to immune attack. The patients in the study were treated with MPDL3280A, a drug being developed by Genentech, a member of the Roche group.
At six weeks, the objective response rate (ORR) was 43%; at 12 weeks, the ORR was 52% in patients with PD-L1-positive tumors. A complete response — one showing no evidence of tumors — was seen in 7% of PD-L1 patients. In patients with PD-L1-negative tumors, the response rate was 11%.
The results in advanced bladder cancer patients "point to a new era in cancer treatment for a disease that has not seen a major advancement since the introduction of cisplatin-based combination therapy in the 1980s," said the study's senior author Daniel P. Petrylak, M.D., professor of medicine and urology at Yale Cancer Center and Yale School of Medicine. "We look forward to opening the phase II trial at Yale in June to confirm these findings."
Yale Cancer Center enrolled 12 of the 68 patients on the trial at Smilow Cancer Hospital at Yale-New Haven.
INFORMATION:
Other authors on the study were Thomas Powles, Nicholas J. Vogelzang, Gregg Daniel Fine, Joseph Paul Eder, Fadi S. Braiteh, Yohann Loriot, Cristina Cruz Zambrano, Joaquim Bellmunt, Howard A. Burris, Siew-leng Melinda Teng, Xiaodong Shen, Hartmut Koeppen, Priti S. Hegde, Daniel S. Chen, Barts Cancer Institute, Queen Mary University Hospital of London, London, United Kingdom; University of Nevada School of Medicine and US Oncology/Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Genentech, Inc., South San Francisco, CA; Yale Cancer Center, New Haven, CT; Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Gustave Roussy, Villejuif, France; Vall d'Hebron University Hospital, Barcelona, Spain; Bladder Cancer Center, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA; Sarah Cannon Research Institute, Nashville, TN; Genentech Inc., a member of the Roche group, South San Francisco, CA. As part of Yale-New Haven Hospital, Smilow Cancer Hospital is Magnet-designated by the American Nurses Credentialing Center.
Yale Cancer Center: http://yalecancercenter.org/index.aspx
Smilow Cancer Hospital at Yale-New Haven: http://www.ynhh.org/smilow-cancer-hospital/default.aspx
Immune therapy for advanced bladder cancer yields promising results
2014-05-31
ELSE PRESS RELEASES FROM THIS DATE:
Phase 3 study strengthens support of ibrutinib as second-line therapy for CLL
2014-05-31
COLUMBUS, Ohio – In a head-to-head comparison of two Food and Drug Administration-approved drugs for the treatment of relapsed chronic lymphocytic leukemia (CLL), ibrutinib significantly outperformed ofatumumab as a second-line therapy, according to a multicenter interim study published in the OnLine First edition of the New England Journal of Medicine. Ibrutinib (Imbruvica) is the first drug designed to target Bruton's tyrosine kinase (BTK), a protein essential for CLL-cell survival and proliferation.
CLL, the most common form of leukemia, causes a gradual increase ...
Mount Sinai researchers to present studies at American Society of Clinical Oncology Meeting
2014-05-31
(New York – UNDER EMBARGO May 31, 2014) Icahn School of Medicine at Mount Sinai researchers will present several landmark studies at the 2014 American Society of Clinical Oncology (ASCO) meeting May 30-June 3, 2014 in Chicago, including data on new treatment approaches for thyroid, head and neck, and recurrent ovarian cancers; and new biomarkers for bile duct cancers.
Highlights of Mount Sinai research at ASCO:
Phase II Trial on the Combination of Bevacizumab and Irinotecan in Recurrent Ovarian Cancer (Under Embargo Until SATURDAY, MAY 31, 8:00 – 11:45 AM)
In a study ...
Researchers take a major step towards better diagnosis and treatment of osteoporosis
2014-05-31
A new target that may be critical for the treatment of osteoporosis, a disease which affects about 25% of post-menopausal women, has been discovered by a group of researchers in The Netherlands and in Germany. Professor Brunhilde Wirth, Head of the Institute of Human Genetics, University of Cologne, Germany, will tell the annual conference of the European Society of Human Genetics tomorrow (Sunday) that new studies in zebrafish and mice have shown that injection of human plastin 3 (PLS3) or related proteins in zebrafish where PLS3 action has been suppressed can replace ...
New genetic sequencing methods mean quicker, cheaper, and accurate embryo screening
2014-05-31
Results from the first study of the clinical application of next generation DNA sequencing (NGS) in screening embryos for genetic disease prior to implantation in patients undergoing in-vitro fertilisation treatments show that it is an effective reliable method of selecting the best embryos to transfer, the annual conference of the European Society of Human Genetics will hear tomorrow (Sunday). Dr Francesco Fiorentino, from the GENOMA Molecular Genetics Laboratory, Rome, Italy, will say that his team's research has shown that NGS, a high throughput sequencing method, has ...
'Often and early' gives children a taste for vegetables
2014-05-31
Exposing infants to a new vegetable early in life encourages them to eat more of it compared to offering novel vegetables to older children, new research from the University of Leeds suggests.
The researchers, led by Professor Marion Hetherington in the Institute of Psychological Sciences, also found that even fussy eaters are able to eat a bit more of a new vegetable each time they are offered it.
The research, involving babies and children from the UK, France and Denmark, also dispelled the popular myth that vegetable tastes need to be masked or given by stealth in ...
Building a better blood vessel
2014-05-30
Boston, MA – The tangled highway of blood vessels that twists and turns inside our bodies, delivering essential nutrients and disposing of hazardous waste to keep our organs working properly has been a conundrum for scientists trying to make artificial vessels from scratch. Now a team from Brigham and Women's Hospital (BWH) has made headway in fabricating blood vessels using a three-dimensional (3D) bioprinting technique.
The study is published online this month in Lab on a Chip.
"Engineers have made incredible strides in making complex artificial tissues such as ...
Eradicating invasive species sometimes threatens endangered ones
2014-05-30
What should resource managers do when the eradication of an invasive species threatens an endangered one?
In results of a study published this week in the journal Science, researchers at the University of California, Davis, examine one such conundrum now taking place in San Francisco Bay.
The study was led by UC Davis researcher Adam Lampert.
"This work advances a framework for cost-effective management solutions to the conflict between removing invasive species and conserving biodiversity," said Alan Tessier, acting deputy division director in the National Science ...
New NASA/JAXA precipitation satellite passes check-out, starts mission
2014-05-30
The new Global Precipitation Measurement Core Observatory satellite is now in the hands of the engineers who will fly the spacecraft and ensure the steady flow of data on rain and snow for the life of the mission. The official handover to the Earth Science Mission Operations team at NASA's Goddard Space Flight Center in Greenbelt, Maryland, on May 29, marked the end of a successful check-out period.
The Global Precipitation Measurement (GPM) mission is a joint mission between NASA and the Japan Aerospace Exploration Agency. Its Core Observatory launched on Feb. 27, 2014, ...
Wallow Fire study suggests there may be multiple paths to fuel reduction in the WUI
2014-05-30
Conservative fuel treatments designed to reduce fire severity while still providing forest cover and wildlife habitat worked equally as well as more intensive treatments in allowing for the protection of homes during the 2011 Wallow Fire, a study published in the journal Forest Ecology and Management has found. The distance into the treated area where fire severity was reduced varied, however, between these different thinning approaches where fuels were reduced. The findings suggest that there may be multiple paths to fuel treatment design around the wildland-urban interface ...
A first for NASA's IRIS: Observing a gigantic eruption of solar material
2014-05-30
VIDEO:
A coronal mass ejection burst off the side of the sun on May 9, 2014. The giant sheet of solar material erupting was the first CME seen by NASA's Interface...
Click here for more information.
A coronal mass ejection, or CME, surged off the side of the sun on May 9, 2014, and NASA's newest solar observatory caught it in extraordinary detail. This was the first CME observed by the Interface Region Imaging Spectrograph, or IRIS, which launched in June 2013 to peer into ...